KDM6A and cancer: GSK-J4, developed as a specific inhibitor of KDM6A/B to enhance H3K27 methylation, has demonstrated anti-cancer abilities by reducing tumor cell proliferation and inducing apoptosis in various studies [16,17,18,19].